Tipifarnib in Treating Patients With Recurrent Bladder Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary
for tumor cell growth.
PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who
have recurrent bladder cancer.